Associate Professor Michael Patrick Hay

BSc (Hons), PhD

Director - ACSRC

In: Auckland Cancer Society Research Centre » Medical Science » Faculty of Medical and Health Sciences

Biography

Michael Hay obtained his BSc (Hons) and PhD in Chemistry from The University of Canterbury, New Zealand. After postdoctoral positions at Imperial College, London, and the University of Auckland, Michael was appointed as a Research Fellow in the Auckland Cancer Society Research Centre in 1991. He was appointed as an Associate Professor in 2011 and leads a group investigating tumour selective drug delivery targeting the tumour microenvironment. Michael was appointed Director of the ACSRC in 2020.

Research interests:

Medicinal chemistry
Drug design
Drug development
DNA damage response
Hypoxia activated prodrugs
Prodrugs
Cancer research
Radiotherapy
Hypoxia

Research | Current

Michael is interested in developing novel therapeutics that target the tumour microenvironment through bioreductive mechanisms and/or selective target inhibition. Current research interests include:

Discovery of new hypoxia-activated prodrugs
Development of nitroimidazole-based radiosensitisers
Development of novel agents targeting DNA damage response pathways.
Development of hypoxia-selective cytotoxins and radiation response modifiers based on the 1,2,4-benzotriazine dioxide core.
Design and synthesis of drugs that target hypoxia-inducible factor (HIF-1alpha).

Distinctions/Honours

Fellow of the New Zealand Institute of Chemistry

Committees/Professional groups/Services

Member of the Medical Committee Auckland Medical Research Foundation

Member of the Biotechnology and Biomedical Sciences Committee, Australian Institute of Nuclear Sciences and Engineering

Selected publications and creative works (Research Outputs)

Hendrikse, E. R., Liew, L. P., Bower, R. L., Bonnet, M., Jamaluddin, M. A., Prodan, N., ... Smith, D. M. (2020). Identification of Small-Molecule Positive Modulators of Calcitonin-like Receptor-Based Receptors. ACS Pharmacology & Translational Science, 3 (2), 305-320. 10.1021/acsptsci.9b00108
URL: http://hdl.handle.net/2292/52400
Other University of Auckland co-authors: Erica Hendrikse, Aqfan Jamaluddin
Lee, T. W., Wong, W. W., Dickson, B. D., Lipert, B., Cheng, G. J., Hunter, F. W., ... Wilson, W. R. (2019). Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia. International journal of radiation biology, 95 (12), 1597-1612. 10.1080/09553002.2019.1664787
Other University of Auckland co-authors: Francis Hunter, Benjamin Dickson, Barbara Lipert, Way Wong
Wong, W. W., Jackson, R. K., Liew, L. P., Dickson, B. D., Cheng, G. J., Lipert, B., ... Hay, M. P. (2019). Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361. Biochemical pharmacology, 16910.1016/j.bcp.2019.113641
URL: http://hdl.handle.net/2292/50047
Other University of Auckland co-authors: Barbara Lipert, Way Wong, Benjamin Dickson, Yongchuan Gu, Francis Hunter, Lydia Liew
Jackson, R. K., Liew, L. P., & Hay, M. P. (2019). Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs. Clinical oncology (Royal College of Radiologists (Great Britain)), 31 (5), 290-302. 10.1016/j.clon.2019.02.004
URL: http://hdl.handle.net/2292/48301
Other University of Auckland co-authors: Lydia Liew
Dickson, B. D., Wong, W. W., Wilson, W. R., & Hay, M. P. (2019). Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors. Molecules (Basel, Switzerland), 24 (8).10.3390/molecules24081559
URL: http://hdl.handle.net/2292/46826
Other University of Auckland co-authors: Benjamin Dickson, Way Wong
Liew, L. P., Singleton, D. C., Wong, W. W., Cheng, G. J., Jamieson, S. M. F., & Hay, M. P. (2019). Hypoxia‐Activated Prodrugs of PERK Inhibitors. Chemistry - An Asian Journal, 14 (8), 1238-1248. 10.1002/asia.201801826
URL: http://hdl.handle.net/2292/48401
Other University of Auckland co-authors: Lydia Liew, Dean Singleton, Way Wong, Stephen Jamieson
Lu, M., Flanagan, J. U., Langley, R. J., Hay, M. P., & Perry, J. K. (2019). Targeting growth hormone function: strategies and therapeutic applications. Signal transduction and targeted therapy, 410.1038/s41392-019-0036-y
URL: http://hdl.handle.net/2292/47899
Other University of Auckland co-authors: Ries Langley, Jo Perry, Jack Flanagan
Chernikova, S. B., Nguyen, R. B., Truong, J. T., Mello, S. S., Stafford, J. H., Hay, M. P., ... Henry, S. (2018). Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. The Journal of clinical investigation, 128 (12), 5307-5321. 10.1172/jci87191
URL: http://hdl.handle.net/2292/45644